Istesso adds a further £4 million to fundraise

Istesso adds a further £4 million to fundraise

Istesso Limited (“Istesso’’) today announces that it has completed a second close of its recently reported financing, adding a further £4 million to the £6 million raised in December and bringing the total amount to £10 million.

For further information, please contact:

Istesso Limited

Dr Sam Williams, Executive Chairman +44 207 444 0066

Notes to Editors

About Istesso

Istesso is a drug discovery and development company working in the field of immunometabolism. Istesso’s products work by reprogramming cellular metabolism and have applications in autoimmune conditions such as rheumatoid arthritis and multiple sclerosis, as well as cancer. For more information please visit www.istesso.co.uk.

ENDS

Istesso
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

More information about our Privacy Policy